The Phosphoinositide-3 kinase survival signaling mechanism in sepsis

Shock

Volumn 34, Issue 5, 2010, Pages 442-449

  Manukyan, Mariuxi C ^a   Weil, Brent R ^a   Wang, Yue ^a   Abarbanell, Aaron M ^a   Herrmann, Jeremy L ^a   Poynter, Jeffrey A ^a   Meldrum, Daniel R ^a,b  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

host defense; immune response; inflammation; PI3K; septic shock

Indexed keywords

CASPASE 3; CASPASE 9; CATHEPSIN B; FAS LIGAND; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; ISOPROTEIN; LIPOPOLYSACCHARIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXO; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; CATALYSIS; CELL FUNCTION; CELL SURVIVAL; CYTOKINE PRODUCTION; ENZYME SUBSTRATE; HEART MUSCLE INJURY; HOST RESISTANCE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PROTECTION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UBIQUITINATION;

ADAPTIVE IMMUNITY; ANIMALS; CELL SURVIVAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; MULTIPLE ORGAN FAILURE; NF-KAPPA B; PERITONITIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN ISOFORMS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SEPSIS; SIGNAL TRANSDUCTION;

EID: 78149282485     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181e14ea9     Document Type: Review

References (105)

1. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296(5573):1655-1657, 2002.
2. Lawlor MA, Alessi DR: PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114 (Pt 16):2903-2910, 2001.
3. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, Evan G: Suppression of c-Myc-induced apoptosis by Ras signalling through PI (3) K and PKB. Nature 385(6616):544-548, 1997.
4. Fruman DA, Bismuth G: Fine tuning the immune response with PI3K. Immunol Rev 228(1):253-272, 2009.
5. Koyasu S: The role of PI3K in immune cells. Nat Immunol 4(4):313-319, 2003.
6. Slotman GJ, Friedman B, Brathwaite C, Mure AJ, Quinn JV, Shapiro E: Interleukin-1 mediates increased plasma levels of eicosanoids and cytokines in patients with sepsis syndrome. Shock 4(5):318-323, 1995.
7. Finnerty CC, Herndon DN, Chinkes DL, Jeschke MG: Serum cytokine differences in severely burned children with and without sepsis. Shock 27(1):4-9, 2007.
8. Abraham E, Singer M: Mechanisms of sepsis-induced organ dysfunction. Crit Care Med 35(10):2408-2416, 2007.
9. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 348(2):138-150, 2003.
10. Gauglitz GG, Song J, Herndon DN, Finnerty CC, Boehning D, Barral JM, Jeschke MG: Characterization of the inflammatory response during acute and post-acute phases after severe burn. Shock 30(5):503-507, 2008.
11. Smith JA: Neutrophils, host defense, and inflammation: a double-edged sword. J Leukoc Biol 56(6):672-686, 1994.
12. Tsujimoto H, Ono S, Efron PA, Scumpia PO, Moldawer LL, Mochizuki H: Role of Toll-like receptors in the development of sepsis. Shock 29(3):315-321, 2008.
13. Kobbe P, Vodovotz Y, Kaczorowski DJ, Mollen KP, Billiar TR, Pape HC: Patterns of cytokine release and evolution of remote organ dysfunction after bilateral femur fracture. Shock 30(1):43-47, 2008.
14. O'Dwyer MJ, Mankan AK, Stordeur P, O'Connell B, Duggan E, White M, Kelleher DP, McManus R, Ryan T: The occurrence of severe sepsis and septic shock are related to distinct patterns of cytokine gene expression. Shock 26(6):544-550, 2006.
15. Wheeler DS, Lahni PM, Denenberg AG, Poynter SE, Wong HR, Cook JA, Zingarelli B: Induction of endotoxin tolerance enhances bacterial clearance and survival in murine polymicrobial sepsis. Shock 30(3):267-273, 2008.
16. Salomao R, Martins PS, Brunialti MK, Fernandes Mda L, Martos LS, Mendes ME, Gomes NE, Rigato O: TLR signaling pathway in patients with sepsis. Shock 30 (Suppl 1):73-77, 2008.
17. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, et al.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 273(12):934-941, 1995.
18. Poeze M, Froon AH, Ramsay G, Buurman WA, Greve JW: Decreased organ failure in patients with severe SIRS and septic shock treated with the plateletactivating factor antagonist TCV-309: a prospective, multicenter, doubleblind, randomized phase II trial. TCV-309 Septic Shock Study Group. Shock 14(4):421-428, 2000.
19. Remick DG, Ward PA: Evaluation of endotoxin models for the study of sepsis. Shock 24 (Suppl 1):7-11, 2005.
20. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10):699-709, 2001.
21. Haberstroh J, Wiese K, Geist A, Dursunoglu GB, Gippner-Steppert C, Jochum M, von Specht BU: Effect of delayed treatment with recombinant human granulocyte colony-stimulating factor on survival and plasma cytokine levels in a non-neutropenic porcine model of Pseudomonas aeruginosa sepsis. Shock 9(2):128-134, 1998.
22. Moubarak P, Zilker S, Wolf H, Hofner B, Kneib T, Kuchenhoff H, Jauch KW, Hartl WH: Activity-guided antithrombin III therapy in severe surgical sepsis: efficacy and safety according to a retrospective data analysis. Shock 30(6):634-641, 2008.
23. Weichhart T, Saemann MD: The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Ann Rheum Dis 67 (Suppl 3):iii70-iii74, 2008.
24. Guha M, Mackman N: The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells. J Biol Chem 277(35):32124-32132, 2002.
25. Wrann CD, Tabriz NA, Barkhausen T, Klos A, van Griensven M, Pape HC, Kendoff DO, Guo R, Ward PA, Krettek C, et al.: The phosphatidylinositol 3-kinase signaling pathway exerts protective effects during sepsis by controlling C5a-mediated activation of innate immune functions. J Immunol 178(9):5940-5948, 2007.
26. Brazil DP, Hemmings BA: Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 26(11):657-664, 2001.
27. Wang M, Wang Y, Weil B, Abarbanell A, Herrmann J, Tan J, Kelly M, Meldrum DR: Estrogen receptor beta mediates increased activation of PI3K/Akt signaling and improved myocardial function in female hearts following acute ischemia. Am J Physiol Regul Integr Comp Physiol 296 (4):R972-R978, 2009.
28. You W, Min X, Zhang X, Qian B, Pang S, Ding Z, Li C, Gao X, Di R, Cheng Y, et al.: Cardiac-specific expression of heat shock protein 27 attenuated endotoxin-induced cardiac dysfunction and mortality in mice through a PI3K/Akt-dependent mechanism. Shock 32(1):108-117, 2009.
29. Bommhardt U, Chang KC, Swanson PE, Wagner TH, Tinsley KW, Karl IE, Hotchkiss RS: Akt decreases lymphocyte apoptosis and improves survival in sepsis. J Immunol 172(12):7583-7591, 2004.
30. Fukao T, Tanabe M, Terauchi Y, Ota T, Matsuda S, Asano T, Kadowaki T, Takeuchi T, Koyasu S: PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat Immunol 3(9):875-881, 2002.
31. Dugo L, Collin M, Allen DA, Patel NS, Bauer I, Mervaala EM, Louhelainen M, Foster SJ, Yaqoob MM, Thiemermann C: GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med 33(9):1903-1912, 2005.
32. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91(2):231-241, 1997.
33. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science 282(5392):1318-1321, 1998.
34. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96(6):857-868, 1999.
35. Burgering BM, Kops GJ: Cell cycle and death control: long live Forkheads. Trends Biochem Sci 27(7):352-360, 2002.
36. Dugo L, Collin M, Thiemermann C: Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation. Shock 27(2):113-123, 2007.
37. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378(6559):785-789, 1995.
38. Danial NN, Korsmeyer SJ: Cell death: critical control points. Cell 116(2):205-219, 2004.
39. Chen HW, Kuo HT, Wang SJ, Lu TS, Yang RC: In vivo heat shock protein assembles with septic liver NF-kappaB/I-kappaB complex regulating NF-κB activity. Shock 24(3):232-238, 2005.
40. Liu SF, Malik AB: NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 290 (4):L622-L645, 2006.
41. Moine P, McIntyre R, Schwartz MD, Kaneko D, Shenkar R, Le Tulzo Y, Moore EE, Abraham E: NF-kappaB regulatory mechanisms in alveolar macrophages from patients with acute respiratory distress syndrome. Shock 13(2):85-91, 2000.
42. Luo JL, Kamata H, Karin M: The anti-death machinery in IKK/NF-kappaB signaling. J Clin Immunol 25(6):541-550, 2005.
43. Jana M, Jana A, Liu X, Ghosh S, Pahan K: Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of I kappa B alpha in anti-inflammatory effect of gemfibrozil in microglia. J Immunol 179(6):4142-4152, 2007.
44. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401(6748):82-85, 1999.
45. Romashkova JA, Makarov SS: NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401(6748):86-90, 1999.
46. Hacker H, Karin M: Regulation and function of IKK and IKK-related kinases. Sci STKE 2006 (357): re13, 2006.
47. Hazeki K, Nigorikawa K, Hazeki O: Role of phosphoinositide 3-kinase in innate immunity. Biol Pharm Bull 30(9):1617-1623, 2007.
48. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, 3rd, Zentella A, Albert JD, et al.: Shock and tissue injury induced by recombinant human cachectin. Science 234(4775):470-474, 1986.
49. Volman TJ, Hendriks T, Verhofstad AA, Kullberg BJ, Goris RJ: Improved survival of TNF-deficient mice during the zymosan-induced multiple organ dysfunction syndrome. Shock 17(6):468-472, 2002.
50. Cain RJ, Ridley AJ: Phosphoinositide 3-kinases in cell migration. Biol Cell 101(1):13-29, 2009.
51. Lu Y, Zhou J, Xu C, Lin H, Xiao J, Wang Z, Yang B: JAK/STAT and PI3K/AKT pathways form a mutual transactivation loop and afford resistance to oxidative stress-induced apoptosis in cardiomyocytes. Cell Physiol Biochem 21(4):305-314, 2008.
52. Fruman DA, Meyers RE, Cantley LC: Phosphoinositide kinases. Annu Rev Biochem 67:481-507, 1998.
53. Falasca M, Maffucci T: Role of class II phosphoinositide 3-kinase in cell signalling. Biochem Soc Trans 35 (Pt 2):211-214, 2007.
54. Backer JM: The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem J 410(1):1-17, 2008.
55. Kok K, Geering B, Vanhaesebroeck B: Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci 34(3):115-127, 2009.
56. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD: Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 22(7):267-272, 1997.
57. Hawkins PT, Stephens LR: PI3Kgamma is a key regulator of inflammatory responses and cardiovascular homeostasis. Science 318(5847):64-66, 2007.
58. Hawkins PT, Anderson KE, Davidson K, Stephens LR: Signalling through class I PI3Ks in mammalian cells. Biochem Soc Trans 34 (Pt 5):647-662, 2006.
59. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC: Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 30(4):194-204, 2005.
60. Puri KD, Doggett TA, Huang CY, Douangpanya J, Hayflick JS, Turner M, Penninger J, Diacovo TG: The role of endothelial PI3Kgamma activity in neutrophil trafficking. Blood 106(1):150-157, 2005.
61. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, Wu D: Roles of PLC-beta2 and-beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 287(5455):1046-1049, 2000.
62. Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L, Sozzani S, Mantovani A, Altruda F, Wymann MP: Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 287(5455):1049-1053, 2000.
63. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B, Wakeham A, Itie A, Bouchard D, Kozieradzki I, et al.: Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 287(5455):1040-1046, 2000.
64. Yang KY, Arcaroli J, Kupfner J, Pitts TM, Park JS, Strasshiem D, Perng RP, Abraham E: Involvement of phosphatidylinositol 3-kinase gamma in neutrophil apoptosis. Cell Signal 15(2):225-233, 2003.
65. Sylte MJ, Kuckleburg CJ, Atapattu D, Leite FP, McClenahan D, Inzana TJ, Czuprynski CJ: Signaling through interleukin-1 type 1 receptor diminishes Haemophilus somnus lipooligosaccharide-mediated apoptosis of endothelial cells. Microb Pathog 39(4):121-130, 2005.
66. Ha T, Hua F, Grant D, Xia Y, Ma J, Gao X, Kelley J, Williams DL, Kalbfleisch J, Browder IW, et al.: Glucan phosphate attenuates cardiac dysfunction and inhibits cardiac MIF expression and apoptosis in septic mice. Am J Physiol Heart Circ Physiol 291 (4):H1910-H1918, 2006.
67. Madge LA, Li JH, Choi J, Pober JS: Inhibition of phosphatidylinositol 3-kinase sensitizes vascular endothelial cells to cytokine-initiated cathepsindependent apoptosis. J Biol Chem 278(23):21295-21306, 2003.
68. Ha T, Hua F, Liu X, Ma J, McMullen JR, Shioi T, Izumo S, Kelley J, Gao X, Browder W, et al.: Lipopolysaccharide-induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism. Cardiovasc Res 78(3):546-553, 2008.
69. Chao W, Shen Y, Zhu X, Zhao H, Novikov M, Schmidt U, Rosenzweig A: Lipopolysaccharide improves cardiomyocyte survival and function after serum deprivation. J Biol Chem 280(23):21997-22005, 2005.
70. Zhou Z, Gengaro P, Wang W, Wang XQ, Li C, Faubel S, Rivard C, Schrier RW: Role of NF-kappaB and PI 3-kinase/Akt in TNF-alpha-induced cytotoxicity in microvascular endothelial cells. Am J Physiol Renal Physiol 295 (4):F932-F941, 2008.
71. Zhang L, Himi T, Morita I, Murota S: Inhibition of phosphatidylinositol-3 kinase/Akt or mitogen-activated protein kinase signaling sensitizes endothelial cells to TNF-alpha cytotoxicity. Cell Death Differ 8(5):528-536, 2001.
72. Williams DL, Li C, Ha T, Ozment-Skelton T, Kalbfleisch JH, Preiszner J, Brooks L, Breuel K, Schweitzer JB: Modulation of the phosphoinositide 3-kinase pathway alters innate resistance to polymicrobial sepsis. J Immunol 172(1):449-456, 2004.
73. Veres B, Gallyas F Jr, Varbiro G, Berente Z, Osz E, Szekeres G, Szabo C, Sumegi B: Decrease of the inflammatory response and induction of the Akt/protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock. Biochem Pharmacol 65(8):1373-1382, 2003.
74. Zeng H, Wu H, Sloane V, Jones R, Yu Y, Lin P, Gewirtz AT, Neish AS: Flagellin/TLR5 responses in epithelia reveal intertwined activation of inflammatory and apoptotic pathways. Am J Physiol Gastrointest Liver Physiol 290 (1):G96-G108, 2006.
75. Sautin YY, Crawford JM, Svetlov SI: Enhancement of survival by LPA via Erk1/Erk2 and PI 3-kinase/Akt pathways in a murine hepatocyte cell line. Am J Physiol Cell Physiol 281 (6):C2010-C2019, 2001.
76. Gao XP, Zhu X, Fu J, Liu Q, Frey RS, Malik AB: Blockade of class IA phosphoinositide 3-kinase in neutrophils prevents NADPH oxidase activation-and adhesion-dependent inflammation. J Biol Chem 282(9):6116-6125, 2007.
77. Yum HK, Arcaroli J, Kupfner J, Shenkar R, Penninger JM, Sasaki T, Yang KY, Park JS, Abraham E: Involvement of phosphoinositide 3-kinases in neutrophil activation and the development of acute lung injury. J Immunol 167(11):6601-6608, 2001.
78. Wong F, Hull C, Zhande R, Law J, Karsan A: Lipopolysaccharide initiates a TRAF6-mediated endothelial survival signal. Blood 103(12):4520-4526, 2004.
79. Fukao T, Koyasu S: PI3K and negative regulation of TLR signaling. Trends Immunol 24(7):358-363, 2003.
80. Binion DG, Heidemann J, Li MS, Nelson VM, Otterson MF, Rafiee P: Vascular cell adhesion molecule-1 expression in human intestinal microvascular endothelial cells is regulated by PI 3-kinase/Akt/MAPK/NF-kappaB: inhibitory role of curcumin. Am J Physiol Gastrointest Liver Physiol 297 (2):G259-G268, 2009.
81. Bocker U, Yezerskyy O, Feick P, Manigold T, Panja A, Kalina U, Herweck F, Rossol S, Singer MV: Responsiveness of intestinal epithelial cell lines to lipopolysaccharide is correlated with Toll-like receptor 4 but not Tolllike receptor 2 or CD14 expression. Int J Colorectal Dis 18(1):25-32, 2003.
82. Ogawa H, Binion DG, Heidemann J, Theriot M, Fisher PJ, Johnson NA, Otterson MF, Rafiee P: Mechanisms of MAdCAM-1 gene expression in human intestinal microvascular endothelial cells. Am J Physiol Cell Physiol 288 (2):C272-C281, 2005.
83. Walton KL, Holt L, Sartor RB: Lipopolysaccharide activates innate immune responses in murine intestinal myofibroblasts through multiple signaling pathways. Am J Physiol Gastrointest Liver Physiol 296 (3):G601-G611, 2009.
84. Rhee SH, Kim H, Moyer MP, Pothoulakis C: Role of MyD88 in phosphatidylinositol 3-kinase activation by flagellin/toll-like receptor 5 engagement in colonic epithelial cells. J Biol Chem 281(27):18560-18568, 2006.
85. Snoeks L, Weber CR, Turner JR, Bhattacharyya M, Wasland K, Savkovic SD: Tumor suppressor Foxo3a is involved in the regulation of lipopolysaccharideinduced interleukin-8 in intestinal HT-29 cells. Infect Immun 76(10):4677-4685, 2008.
86. Jean-Baptiste E: Cellular mechanisms in sepsis. J Intensive Care Med 22(2):63-72, 2007.
87. Martin M, Rehani K, Jope RS, Michalek SM: Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6(8):777-784, 2005.
88. Fukao T, Yamada T, Tanabe M, Terauchi Y, Ota T, Takayama T, Asano T, Takeuchi T, Kadowaki T, Hata Ji J, et al.: Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice. Nat Immunol 3(3):295-304, 2002.
89. Rajaram MV, Ganesan LP, Parsa KV, Butchar JP, Gunn JS, Tridandapani S: Akt/protein kinase B modulates macrophage inflammatory response to Francisella infection and confers a survival advantage in mice. J Immunol 177(9):6317-6324, 2006.
90. Williams DL, Ozment-Skelton T, Li C: Modulation of the phosphoinositide 3-kinase signaling pathway alters host response to sepsis, inflammation, and ischemia/reperfusion injury. Shock 25(5):432-439, 2006.
91. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, et al.: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebocontrolled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271(23):1836-1843, 1994.
92. Remick D, Manohar P, Bolgos G, Rodriguez J, Moldawer L, Wollenberg G: Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 4(2):89-95, 1995.
93. Hadjiminas DJ, McMasters KM, Peyton JC, Cook MD, Cheadle WG: Passive immunization against tumor necrosis factor and interleukin-1 fails to reduce lung neutrophil sequestration in chronic sepsis. Shock 2(5):376-380, 1994.
94. Li X, Tupper JC, Bannerman DD, Winn RK, Rhodes CJ, Harlan JM: Phosphoinositide 3 kinase mediates Toll-like receptor 4-induced activation of NF-kappa B in endothelial cells. Infect Immun 71(8):4414-4420, 2003.
95. Cario E, Gerken G, Podolsky DK: Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 132(4):1359-1374, 2007.
96. Yu Y, Nagai S, Wu H, Neish AS, Koyasu S, Gewirtz AT: TLR5-mediated phosphoinositide 3-kinase activation negatively regulates flagellin-induced proinflammatory gene expression. J Immunol 176(10):6194-6201, 2006.
97. Li Q, Verma IM: NF-kappaB regulation in the immune system. Nat Rev Immunol 2(10):725-734, 2002.
98. Vermeulen L, De Wilde G, Notebaert S, Vanden Berghe W, Haegeman G: Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol 64 (5-6): 963-970, 2002.
99. Sun Z, Andersson R: NF-kappaB activation and inhibition: a review. Shock 18(2):99-106, 2002.
100. Joshi AR, Chung CS, Song GY, Lomas J, Priester RA, Ayala A: NF-kappaB activation has tissue-specific effects on immune cell apoptosis during polymicrobial sepsis. Shock 18(4):380-386, 2002.
101. Schabbauer G, Tencati M, Pedersen B, Pawlinski R, Mackman N: PI3K-Akt pathway suppresses coagulation and inflammation in endotoxemic mice. Arterioscler Thromb Vasc Biol 24(10):1963-1969, 2004.
102. Kim WK, Hwang SY, Oh ES, Piao HZ, Kim KW, Han IO: TGF-beta1 represses activation and resultant death of microglia via inhibition of phosphatidylinositol 3-kinase activity. J Immunol 172(11):7015-7023, 2004.
103. Medina-Tato DA, Ward SG, Watson ML: Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond. Immunology 121(4):448-461, 2007.
104. Ong E, Gao XP, Predescu D, Broman M, Malik AB: Role of phosphatidylinositol 3-kinase-gamma in mediating lung neutrophil sequestration and vascular injury induced by E. coli sepsis. Am J Physiol Lung Cell Mol Physiol 289 (6):L1094-L1103, 2005.
105. Pahan K, Raymond JR, Singh I: Inhibition of phosphatidylinositol 3-kinase induces nitric-oxide synthase in lipopolysaccharide-or cytokine-stimulated C6 glial cells. J Biol Chem 274(11):7528-7536, 1999.